-
公开(公告)号：US20100098662A1
公开(公告)日：2010-04-22
申请号：US12641690
申请日：2009-12-18
IPC分类号： A61K38/21 , A61K31/4196 , A61P1/16 , A61K31/70
CPC分类号： A61K31/4196
摘要： The invention relates to the use of 4-[3,5-Bis-(2-hydroxyphenyl)-[1,2,4]-triazol-1-yl]benzoic acid (hereinafter referred to as “Compound I”) for the manufacture of pharmaceutical compositions for the treatment of liver diseases in humans in which iron plays a role in pathogenesis, including viral diseases, such as chronic hepatitis C, optionally in conjunction with antiviral agents and for the treatment of non viral diseases, such as non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
摘要翻译： 本发明涉及4- [3,5-双 - （2-羟基苯基） - [1,2,4] - 三唑-1-基]苯甲酸（以下称为“化合物I”）用于 制造用于治疗人在其中发挥铁作用的人类肝病的药物组合物，包括病毒性疾病如慢性丙型肝炎，任选地与抗病毒剂联合用于治疗非病毒性疾病，例如非病毒性疾病， 酒精性脂肪性肝炎和非酒精性脂肪性肝病。
-
2.发明申请公开(公告)号：US20080199428A1
公开(公告)日：2008-08-21
申请号：US11913678
申请日：2006-05-30
IPC分类号： A61K31/4196 , A61K38/21 , A61P43/00
CPC分类号： A61K31/4196
摘要： The invention relates to the use of 4-[3,5-Bis-(2-hydroxyphenyl)-[1,2,4]-triazol-1-yl]benzoic acid (hereinafter referred to as “Compound I”) for the manufacture of pharmaceutical compositions for the treatment of liver diseases in humans in which iron plays a role in pathogenesis, including viral diseases, such as chronic hepatitis C, optionally in conjunction with antiviral agents and for the treatment of non viral diseases, such as non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
摘要翻译： 本发明涉及4- [3,5-双 - （2-羟基苯基） - [1,2,4] - 三唑-1-基]苯甲酸（以下称为“化合物I”）用于 制造用于治疗人在其中发挥铁作用的人类肝病的药物组合物，包括病毒性疾病如慢性丙型肝炎，任选地与抗病毒剂联合用于治疗非病毒性疾病，例如非病毒性疾病， 酒精性脂肪性肝炎和非酒精性脂肪性肝病。
-
搜索结果
2 条记录 (耗时 0.01 秒)
